Jpmorgan Chase & CO Summit Therapeutics Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 163,750 shares of SMMT stock, worth $3.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

163,750

Previous 249,667 34.41%

Holding current value

$3.27 Million

Previous $1.03 Million 23.62%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$2.39 - $10.92 $205,341 - $938,213	-85,917 Reduced 34.41%	163,750 $1.28 Million
Q1 2024 May 10, 2024	SELL	$2.55 - $5.07 $118,671 - $235,947	-46,538 Reduced 15.71%	249,667 $1.03 Million
Q4 2023 Feb 12, 2024	BUY	$1.67 - $2.83 $137,592 - $233,166	82,391 Added 38.53%	296,205 $773,000
Q3 2023 Nov 14, 2023	BUY	$1.54 - $2.42 $149,994 - $235,705	97,399 Added 83.67%	213,814 $399,000
Q2 2023 Aug 11, 2023	BUY	$1.32 - $2.81 $123,170 - $262,203	93,311 Added 403.87%	116,415 $292,000
Q1 2023 May 11, 2023	BUY	$1.38 - $5.41 $13,140 - $51,514	9,522 Added 70.11%	23,104 $40,000
Q4 2022 Feb 13, 2023	BUY	$0.68 - $5.31 $809 - $6,318	1,190 Added 9.6%	13,582 $58,000
Q3 2022 Nov 14, 2022	BUY	$0.89 - $1.63 $6,458 - $11,828	7,257 Added 141.32%	12,392 $15,000
Q2 2022 Aug 11, 2022	SELL	$0.92 - $2.38 $17,341 - $44,860	-18,849 Reduced 78.59%	5,135 $6,000
Q1 2022 May 11, 2022	SELL	$2.0 - $3.45 $19,006 - $32,785	-9,503 Reduced 28.38%	23,984 $58,000
Q4 2021 Feb 10, 2022	BUY	$2.45 - $5.64 $40,532 - $93,308	16,544 Added 97.65%	33,487 $90,000
Q3 2021 Nov 12, 2021	BUY	$4.83 - $8.27 $81,834 - $140,118	16,943 New	16,943 $85,000

Others Institutions Holding SMMT

# of Institutions

146

Shares Held

66.2M

Call Options Held

1.05M

Put Options Held

1.02M

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $4.02B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Summit Therapeutics Inc. Transaction History